Lawrence Fong Selected Research

sipuleucel-T (APC8015)

1/2021	IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
1/2021	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
1/2021	Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy.
12/2020	Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
1/2020	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
1/2019	Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.
1/2018	Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies.
1/2018	Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
1/2018	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
2/2017	3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lawrence Fong Research Topics

Disease

80	Neoplasms (Cancer) 01/2022 - 03/2002
67	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2003
10	Melanoma (Melanoma, Malignant) 01/2021 - 01/2012
8	Disease Progression 01/2021 - 06/2006
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 09/2011
7	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2007
4	Carcinoma (Carcinomatosis) 01/2022 - 01/2016
4	Infections 01/2021 - 11/2002
4	Fatigue 01/2020 - 07/2006
3	Inflammation (Inflammations) 01/2022 - 10/2019
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 04/2016
3	Exanthema (Rash) 09/2019 - 03/2007
3	Colorectal Neoplasms (Colorectal Cancer) 08/2015 - 10/2007
2	Neutropenia 01/2022 - 09/2009
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2021 - 01/2018
2	Prostatitis 01/2021 - 07/2009
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 09/2014
2	Adenocarcinoma 01/2021 - 03/2008
2	Microsatellite Instability 03/2020 - 08/2015
2	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 09/2014
2	Autoimmune Diseases (Autoimmune Disease) 09/2019 - 11/2006
2	Circulating Neoplastic Cells 12/2017 - 04/2014
1	Hypoxia (Hypoxemia) 01/2022
1	Febrile Neutropenia 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Bites and Stings (Sting) 01/2021
1	Kidney Neoplasms (Kidney Cancer) 01/2021
1	Mesothelioma 01/2021
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2021

Drug/Important Bio-Agent (IBA)

20	AntigensIBA 01/2022 - 03/2002
19	Immune Checkpoint InhibitorsIBA 10/2021 - 10/2012
18	sipuleucel-T (APC8015)FDA Link 01/2021 - 07/2006
17	AndrogensIBA 01/2022 - 10/2003
12	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 10/2003
12	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021 - 06/2006
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2011
10	IpilimumabIBA 01/2021 - 03/2007
8	VaccinesIBA 12/2019 - 07/2006
7	prostatic acid phosphataseIBA 01/2021 - 10/2003
7	AutoantigensIBA 01/2017 - 07/2006
6	pembrolizumabIBA 01/2022 - 01/2017
6	atezolizumabIBA 01/2021 - 01/2018
6	Peptides (Polypeptides)IBA 01/2021 - 10/2007
6	AntibodiesIBA 01/2019 - 05/2006
6	Proteins (Proteins, Gene)FDA Link 07/2009 - 10/2003
5	CytokinesIBA 01/2022 - 12/2007
5	Bevacizumab (Avastin)FDA Link 01/2021 - 07/2006
5	LigandsIBA 09/2019 - 01/2014
5	Cancer VaccinesIBA 11/2016 - 10/2003
4	Prednisone (Sone)FDA LinkGeneric 01/2022 - 12/2014
4	Sunitinib (Sutent)FDA Link 01/2021 - 01/2018
4	Abiraterone AcetateIBA 12/2017 - 03/2010
4	Monoclonal AntibodiesIBA 03/2014 - 11/2008
3	Docetaxel (Taxotere)FDA Link 01/2022 - 01/2017
3	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 01/2020
3	Pharmaceutical PreparationsIBA 01/2021 - 10/2006
3	Interleukin-12 (IL 12)IBA 01/2020 - 04/2011
3	Ketoconazole (Nizoral)FDA LinkGeneric 12/2014 - 12/2007
3	Hormones (Hormone)IBA 01/2012 - 07/2006
2	B7-H1 AntigenIBA 01/2022 - 01/2020
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2021
2	InterferonsIBA 01/2022 - 01/2019
2	Protein Isoforms (Isoforms)IBA 01/2021 - 09/2014
2	MesothelinIBA 01/2021 - 11/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2018
2	enzalutamideIBA 01/2021 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2020 - 02/2018
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 01/2016
2	CTLA-4 AntigenIBA 01/2019 - 07/2010
2	PlatinumIBA 01/2018 - 01/2017
2	abirateroneIBA 01/2018 - 12/2017
2	Everolimus FDA Link 11/2016 - 09/2011
2	sargramostim (Leukine)FDA Link 09/2015 - 06/2006
2	Biological ProductsIBA 01/2014 - 10/2006
2	Insulin-Like PeptidesIBA 07/2012 - 01/2012
2	Tyrosine Kinase InhibitorsIBA 09/2011 - 09/2009
1	ribociclibIBA 01/2022
1	Filgrastim (Neupogen)FDA Link 01/2022
1	Cyclic AMP (AMP, Cyclic)IBA 01/2022
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2022
1	cyclopropapyrroloindoleIBA 10/2021
1	durvalumabIBA 07/2021
1	Interleukin-7 (Interleukin 7)IBA 01/2021
1	Androgen Receptors (Androgen Receptor)IBA 01/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2021
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021
1	Muromonab-CD3 (Muromonab CD3)FDA Link 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	Radium-223IBA 01/2021
1	Biocompatible Materials (Biomaterials)IBA 01/2021
1	ABBV-428IBA 01/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	LipopolysaccharidesIBA 01/2021

Therapy/Procedure

53	Immunotherapy 01/2022 - 10/2003
49	Therapeutics 12/2021 - 10/2003
30	Castration 01/2022 - 12/2007
11	Drug Therapy (Chemotherapy) 01/2021 - 05/2006
5	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 11/2014
2	Radiotherapy 01/2020 - 01/2019
2	Neoadjuvant Therapy 04/2016 - 11/2014